Diseases of the cornea resulting in either impaired vision or blindness are estimated to afflict over 35 million individuals globally with over 30,000 cases being added to the list every year.
1 The cornea is transparent and functions as the primary refracting element of the eye, hence, diseases afflicting it translate to thousands in man hours lost and, therefore, a huge loss to the economy. Replacing the affected cornea in part (lamellar or endothelial keratoplasty) or total (penetrating keratoplasty) with a healthy donor tissue is the current accepted standard of care. However, the huge gap in the demand and supply of healthy donor tissues is a well acknowledged bottleneck for timely transplantations in many countries. Given that nearly a half of all the transplantations performed in a year are for replacing only the dysfunctional endothelium,
2 the monolayer of cells that maintain corneal transparency, research has focussed on engineering this layer in the laboratory.
Regeneration or replacement of these cells can be achieved by either directly injecting these cells into the anterior chamber
3 or delivering them as a monolayer using a carrier. The latter might be a better approach because the delivery would be precise, loss of transplanted cells would be lesser resulting in faster visual recovery, and the number of cells required for transplantation may be lesser. Thus, it is important to identify a substrate that closely mimics the native basement membrane of these cells, the Descemet’ membrane, which is a transparent, elastic, thin (5−15 µm) structure composed primarily of collagen and matrix proteins, such as laminin and fibronectin. Several materials have been developed for this purpose, including decellularized corneal stroma, human amniotic membrane, collagen I sheet, silk fibroin, composite materials, hydrogel, gelatin, and synthetic materials.
4–11 However, each of these have limitations in terms of poor tensile strength, low transparency, poor compatibility, poor support for cell growth, or high cost.
Naturally derived silk protein is a potential biomaterial for various tissue engineering applications owing to its biocompatibility, tuneable degradability, remarkable mechanical strength, minimal immunogenicity, and ability to adopt myriad formats (3D scaffolds, nanofibers, hydrogels, thin films etc.).
12–15 Silk films prepared using the mulberry variety Bombyx mori (BM) are optically transparent, easy to handle, and has shown some promise for corneal regeneration by supporting the growth of corneal endothelial and epithelial cells.
11,16–22 However, to achieve confluent growth of these cells on BM, it is required to modify the silk films by Arg-Gly-Asp (RGD) coupling
23,24 or collagen coating.
11 This makes the fabrication process cumbersome and expensive, thus limiting the use of BM silk films for corneal tissue engineering purposes.
18 It is pertinent to note that most prior studies have used the BM silk for corneal regeneration applications whereas, various non-mulberry silk varieties remain largely unexplored. Some of these have been reported to possess cell-binding RGD motifs naturally,
25–27 thus rendering them more suitable for cell-based therapies. Hogerheyde et al. used a wild non-mulberry silk fibroin (NMSF) Antheraea pernyi for corneal epithelial cell transplantation.
28 In another study, Hazra et al. showed the potential of NMSF Antheraea mylitta as a superior alternative for growth of keratocytes and epithelial cells isolated from rat cornea when compared with BM silk.
29
In this study, we report the use of silk protein, isolated from non-mulberry varieties Philosamia ricini (PR) and Antheraea assamensis (AA) for the culture of corneal endothelial cells and assess their ability to support human corneal endothelial growth and function in comparison to BM. We hypothesize that PR and AA would support cell adhesion and growth better than BM due to the natural presence of RGD motifs in these silk varieties.